LIVIVO - Search results -

Search results

Result 1 - 10 of total 41

Search options

Article: Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy.

Palmieri, Raffaele / Billio, Atto / Ferrara, Felicetto / Galimberti, Sara / Lemoli, Roberto M / Todisco, Elisabetta / Moretti, Federico / Venditti, Adriano

Frontiers in oncology

2024 Volume 14, Page(s) 1367393

Abstract: In patients with Acute Myeloid Leukemia (AML), the assessment of disease risk plays a central role in the era of personalized medicine. Indeed, integrating baseline clinical and biological features on a case-by-case basis is not only essential to select ... ...

Abstract	In patients with Acute Myeloid Leukemia (AML), the assessment of disease risk plays a central role in the era of personalized medicine. Indeed, integrating baseline clinical and biological features on a case-by-case basis is not only essential to select which treatment would likely result in a higher probability of achieving complete remission, but also to dynamically customize any subsequent therapeutic intervention. For young high-risk patients with low comorbidities burden and in good general conditions (also called "fit" patients), intensive chemotherapy followed by allogeneic stem cell transplantation still represents the backbone of any therapeutic program. However, with the approval of novel promising agents in both the induction/consolidation and the maintenance setting, the algorithms for the management of AML patients considered eligible for intensive chemotherapy are in constant evolution. In this view, we selected burning issues regarding the identification and management of high-risk AML, aiming to provide practical advice to facilitate their daily clinical management in patients considered eligible for intensive chemotherapy.
Language	English
Publishing date	2024-02-20
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2024.1367393
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: The role of BDNF in major depressive disorder, related clinical features, and antidepressant treatment: Insight from meta-analyses.

Cavaleri, Daniele / Moretti, Federico / Bartoccetti, Alessandra / Mauro, Stefano / Crocamo, Cristina / Carrà, Giuseppe / Bartoli, Francesco

Neuroscience and biobehavioral reviews

2023 Volume 149, Page(s) 105159

Abstract: The brain-derived neurotrophic factor (BDNF) has received considerable attention as a potential biomarker of major depressive disorder (MDD) and antidepressant response. We conducted an overview of meta-analyses investigating the relationship of BDNF ... ...

Abstract	The brain-derived neurotrophic factor (BDNF) has received considerable attention as a potential biomarker of major depressive disorder (MDD) and antidepressant response. We conducted an overview of meta-analyses investigating the relationship of BDNF with MDD, related clinical features, and antidepressant treatment. Based on a systematic screening on main electronic databases, 11 systematic reviews with meta-analyses were included. Available evidence suggests that people with MDD have peripheral and central BDNF levels lower than non-depressed individuals. A negative correlation between blood BDNF and symptom severity emerged, while no association with suicidality was detected. Moreover, an increase in blood BDNF levels after antidepressant treatment, proportional to symptom improvement, was reported. BDNF levels seem to be increased in both treatment responders and remitters, remaining stable in non-responders. Conversely, no variations of BDNF concentrations after non-pharmacological interventions (electroconvulsive therapy, repetitive transcranial magnetic stimulation, and physical activity) were found. The findings of this overview appear consistent with the neurotrophic hypothesis of depression, suggesting that BDNF may play a role in both MDD pathophysiology and pharmacological treatment response.
MeSH term(s)	Humans ; Depressive Disorder, Major/drug therapy ; Brain-Derived Neurotrophic Factor ; Antidepressive Agents/therapeutic use ; Antidepressive Agents/pharmacology ; Transcranial Magnetic Stimulation ; Exercise
Chemical Substances	Brain-Derived Neurotrophic Factor ; Antidepressive Agents
Language	English
Publishing date	2023-04-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	282464-4
ISSN	1873-7528 ; 0149-7634
ISSN (online)	1873-7528
ISSN	0149-7634
DOI	10.1016/j.neubiorev.2023.105159
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1371: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Trapping Mechanisms and Delayed Recombination Processes in Scintillating Ce-Doped Sol–Gel Silica Fibers

Cova, Francesca / Moretti, Federico / Dujardin, Christophe / Chiodini, Norberto / Vedda, Anna

Journal of physical chemistry. 2021 May 19, v. 125, no. 21

2021

Abstract: The carrier trapping and recombination mechanisms occurring in Ce-doped silica fibers, produced by a sol–gel technique, are investigated by combining temperature-dependent steady-state X-ray-excited luminescence, wavelength- and time-resolved ... ...

Abstract	The carrier trapping and recombination mechanisms occurring in Ce-doped silica fibers, produced by a sol–gel technique, are investigated by combining temperature-dependent steady-state X-ray-excited luminescence, wavelength- and time-resolved scintillation measurements, and wavelength-resolved thermally stimulated luminescence, focusing especially on the temperature range from 10 to 320 K. The scintillation decay features a decay time of the order of tens of nanoseconds, characteristic of the parity- and spin-allowed 5d–4f radiative transition of Ce³⁺ ions. In addition, a slow and complex decay contribution in the microsecond timescale is detected. We interpret these features as due to the radiative recombination at Ce centers of carriers freed from a continuous distribution of trapping sites in the forbidden gap as well as to the occurrence of an athermal tunneling recombination process between traps and Ce³⁺ ions. This interpretation is reinforced by good agreement between independent evaluations of trap depths and lifetimes obtained by both the numerical analysis of scintillation time decays and thermally stimulated luminescence experiments.
Keywords	luminescence ; physical chemistry ; silica ; temperature
Language	English
Dates of publication	2021-0519
Size	p. 11489-11498.
Publishing place	American Chemical Society
Document type	Article
Note	NAL-AP-2-clean
ISSN	1932-7455
DOI	10.1021/acs.jpcc.0c11073
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Exploring depression in people with schizophrenia spectrum disorders: A cross-sectional analysis of the clinical relationship with Positive and Negative Syndrome Scale dimensions.

Bartoli, Francesco / Calabrese, Angela / Moretti, Federico / Castiglioni, Marta / Prestifilippo, Luca / De Pietra, Aldo / Gazzola, Marco / Camera, Paolo / Crocamo, Cristina / Carrà, Giuseppe

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

2024

Abstract: Objective: Evidence on the relationship of depression with clinical dimensions of schizophrenia remains limited. This cross-sectional study aimed at exploring the association of depression with the Positive and Negative Syndrome Scale (PANSS) dimensions ...

Abstract	Objective: Evidence on the relationship of depression with clinical dimensions of schizophrenia remains limited. This cross-sectional study aimed at exploring the association of depression with the Positive and Negative Syndrome Scale (PANSS) dimensions in people with schizophrenia spectrum disorders (SSD). Methods: Trained assessors administered PANSS to measure core symptoms of schizophrenia and the Calgary Depression Scale for Schizophrenia (CDSS) to measure depressive features. Multiple logistic regression analyses were carried out to analyse the association of depression with PANSS overall score and related dimensions. Results: We included 231 inpatients with SSD (mean age:42.4±12.9 years; males: 58.9%; mean PANSS overall score:82.5±20.1; drug-free or naïve: 39.3%), including 78 (33.8%) with clinically significant depressive symptoms. Depression was associated with higher overall (regression coefficient [coeff.], standard error [SE]: 0.029, 0.008; p<0.001) and General Psychopathology (coeff., SE: 0.118, 0.023; p<0.001) PANSS scores. We found an inverse relationship between depression and positive symptoms (coeff., SE: -0.088, 0.028; p=0.002). No association between depressive and negative symptoms was estimated. Conclusions: Despite some limitations, our study shows that people affected by SSD with depressive features are likely to show more overall and general psychopathology symptoms, though lower positive symptoms. Additional studies are needed to explore the generalizability of our findings.
Language	English
Publishing date	2024-01-28
Publishing country	Brazil
Document type	Journal Article
ZDB-ID	2024119-7
ISSN	1809-452X ; 1809-452X
ISSN (online)	1809-452X
ISSN	1809-452X
DOI	10.47626/1516-4446-2023-3418
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review.

Bartoli, Francesco / Riboldi, Ilaria / Bachi, Bianca / Calabrese, Angela / Moretti, Federico / Crocamo, Cristina / Carrà, Giuseppe

Journal of clinical medicine

2021 Volume 10, Issue 6

Abstract: Although cannabis' major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential ... ...

Abstract	Although cannabis' major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders.
Language	English
Publishing date	2021-03-22
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm10061303
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials.

Bartoli, Francesco / Cavaleri, Daniele / Bachi, Bianca / Moretti, Federico / Riboldi, Ilaria / Crocamo, Cristina / Carrà, Giuseppe

Journal of psychiatric research

2021 Volume 143, Page(s) 230–238

Abstract: Several drugs previously tested in clinical trials and approved for different indications have been repurposed for bipolar disorder. We carried out a systematic meta-review of meta-analyses of randomized placebo-controlled trials investigating repurposed ...

Abstract	Several drugs previously tested in clinical trials and approved for different indications have been repurposed for bipolar disorder. We carried out a systematic meta-review of meta-analyses of randomized placebo-controlled trials investigating repurposed drugs as adjunctive treatments for mania and bipolar depression. We performed a critical appraisal using 'A MeaSurement Tool to Assess systematic Reviews' Version 2 (AMSTAR 2). We synthesized results on efficacy, tolerability, and safety, assessing evidence quality according to the 'Grading of Recommendations, Assessment, Development and Evaluations' (GRADE) approach. Our systematic search identified nine eligible studies investigating 12 drugs, four for mania and eight for bipolar depression. The quality of reporting was heterogeneous according to AMSTAR 2. In mania, allopurinol (for symptoms reduction and remission at 4-8 weeks) and tamoxifen (for response and symptoms reduction at 4-6 weeks) showed higher efficacy than placebo, with low and very low quality of evidence, respectively. Concerning bipolar depression, modafinil/armodafinil (for response, remission, and symptoms reduction at 6-8 weeks) and pramipexole (for response and symptoms reduction at 6 weeks) were superior to placebo, despite the low quality of evidence. Results on the efficacy of celecoxib and N-acetylcysteine were of low quality and limited to certain outcomes. Overall, the lack of evidence of high and moderate quality does not allow us to draw firm conclusions on the clinical utility of repurposed drugs as adjunctive treatments for mania and bipolar depression, highlighting the need for additional research.
MeSH term(s)	Bipolar Disorder/drug therapy ; Humans ; Mania ; Meta-Analysis as Topic ; Modafinil ; Pharmaceutical Preparations ; Randomized Controlled Trials as Topic
Chemical Substances	Pharmaceutical Preparations ; Modafinil (R3UK8X3U3D)
Language	English
Publishing date	2021-09-03
Publishing country	England
Document type	Journal Article ; Systematic Review
ZDB-ID	3148-3
ISSN	1879-1379 ; 0022-3956
ISSN (online)	1879-1379
ISSN	0022-3956
DOI	10.1016/j.jpsychires.2021.09.018
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui I Zs.243: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Innovations in community-based mental health care: an overview of meta-analyses.

Carrà, Giuseppe / Bartoli, Francesco / Capogrosso, Chiara A / Cioni, Riccardo M / Moretti, Federico / Piacenti, Susanna / Riboldi, Ilaria / Crocamo, Cristina / Bebbington, Paul E

International review of psychiatry (Abingdon, England)

2022 Volume 34, Issue 7-8, Page(s) 770–782

Abstract: In the last four decades, mental health services for people with Severe Mental Illness (SMI) have seen asylums replaced by a balanced model of Community Mental Healthcare (CMH). Innovative approaches and strategies in the field of CMH have been ... ...

Abstract	In the last four decades, mental health services for people with Severe Mental Illness (SMI) have seen asylums replaced by a balanced model of Community Mental Healthcare (CMH). Innovative approaches and strategies in the field of CMH have been extensively researched. However, this research has been hampered by issues limiting their capacity to inform clinicians and policymakers. We conducted an overview of meta-analyses of the effectiveness of innovative CMH models focussing on clinical and psychosocial outcomes in comparisons with standard care in adults with SMI. Based on the 12 eligible studies, we appraised, synthesised and graded the resulting evidence. There was moderate quality evidence that case management, Early Intervention Services (EIS) and caregiver-directed interventions were superior to standard care in reducing hospital admission. In relation to psychosocial outcomes, EIS showed high quality evidence of a small effect on global functioning. There was moderate quality evidence for a similar effect of Intensive Case Management, and for a large effect of family intervention. For quality of life, both EIS and self-management education had a small effect, with moderate quality. The level of research about effective CMH models is therefore substantial. However, several gaps related to innovative CMH not yet covered in meta-analytic synthesis, need to be filled.
MeSH term(s)	Adult ; Humans ; Mental Disorders/therapy ; Mental Health ; Mental Health Services ; Quality of Life ; Self-Management ; Meta-Analysis as Topic
Language	English
Publishing date	2022-09-01
Publishing country	England
Document type	Journal Article
ZDB-ID	1018090-4
ISSN	1369-1627 ; 0954-0261
ISSN (online)	1369-1627
ISSN	0954-0261
DOI	10.1080/09540261.2022.2113043
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2819: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia.

Paterno, Giovangiacinto / Palmieri, Raffaele / Tesei, Cristiano / Nunzi, Andrea / Ranucci, Giorgia / Mallegni, Flavia / Moretti, Federico / Meddi, Elisa / Tiravanti, Ilaria / Marinoni, Massimiliano / Page, Camilla / Fagiolo, Solaria / Buzzatti, Elisa / Secchi, Roberto / Gurnari, Carmelo / Maurillo, Luca / Buccisano, Francesco / Venditti, Adriano / Del Principe, Maria Ilaria

Thrombosis research

2024 Volume 236, Page(s) 30–36

Abstract: Coagulation disorders frequently complicate the clinical course of acute myeloid leukemia (AML) patients. This study examined the frequency and prognostic significance, with regards of early mortality, of the presence of overt disseminated intravascular ... ...

Abstract	Coagulation disorders frequently complicate the clinical course of acute myeloid leukemia (AML) patients. This study examined the frequency and prognostic significance, with regards of early mortality, of the presence of overt disseminated intravascular coagulation (DIC) at AML diagnosis and its correlation with clinical and biological characteristics. A retrospective analysis of 351 newly diagnosed non-promyelocytic AML patients was conducted, utilizing the 2018 ISTH DIC-Score criteria to evaluate the presence of overt DIC at AML onset. The study cohort had a median age of 65 years with a predominance of male gender (59 %). Overt DIC was present in 21 % of cases and was associated with advanced age, comorbidities, poor performance status, hyperleukocytosis, LDH levels, NPM1 mutations, expression of CD33 and CD4, and lack of expression of CD34. With a median follow-up of 72 months (3-147 months), the 6-year overall survival (OS) was 17.4 %, with patients having overt DIC showing significantly poorer outcomes (7.2 % compared to 20.3 % of those without DIC, p < 0.001). Patients with overt DIC showed markedly high early mortality rates at 30 (42.5 % vs 8 %), 60 (49.3 % vs 16.9 %), and 120 days (64.4 % vs 25.6 %) from disease onset. In multivariate analysis overt DIC retained its independent prognostic value for early mortality. In conclusion, the prevalence and clinical relevance of DIC in non-promyelocytic AML is not negligible, underlining its potential as an unfavorable prognostic marker. In newly diagnosed patients with AML, early recognition and measure to counteract coagulation disturbances might help mitigate the elevated mortality risk associated with DIC.
MeSH term(s)	Humans ; Male ; Aged ; Female ; Disseminated Intravascular Coagulation/etiology ; Retrospective Studies ; Leukemia, Myeloid, Acute/complications ; Prognosis ; Blood Coagulation
Language	English
Publishing date	2024-02-16
Publishing country	United States
Document type	Journal Article
ZDB-ID	121852-9
ISSN	1879-2472 ; 0049-3848
ISSN (online)	1879-2472
ISSN	0049-3848
DOI	10.1016/j.thromres.2024.02.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 863: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The crystal structure of TlMgCl

Onken, Drew R / Perrodin, Didier / Vogel, Sven C / Bourret, Edith D / Moretti, Federico

Acta crystallographica. Section E, Crystallographic communications

2020 Volume 76, Issue Pt 11, Page(s) 1716–1719

Abstract: The title compound, thallium magnesium trichloride, has been identified as a scintillator with both moderate gamma-stopping power and moderate light yield. Knowledge of its crystal structure is needed for further development. This work determines the ... ...

Abstract	The title compound, thallium magnesium trichloride, has been identified as a scintillator with both moderate gamma-stopping power and moderate light yield. Knowledge of its crystal structure is needed for further development. This work determines the crystal structure of TlMgCl
Language	English
Publishing date	2020-10-06
Publishing country	England
Document type	Journal Article
ZDB-ID	2041947-8
ISSN	2056-9890 ; 1600-5368
ISSN	2056-9890 ; 1600-5368
DOI	10.1107/S2056989020013201
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Cannabidiol for Mood Disorders: A Call for More Research.

Bartoli, Francesco / Bachi, Bianca / Calabrese, Angela / Moretti, Federico / Crocamo, Cristina / Carrà, Giuseppe

Canadian journal of psychiatry. Revue canadienne de psychiatrie

2020 Volume 66, Issue 2, Page(s) 182–183

MeSH term(s)	Bipolar Disorder ; Cannabidiol ; Depressive Disorder, Major ; Humans ; Mood Disorders/drug therapy
Chemical Substances	Cannabidiol (19GBJ60SN5)
Language	English
Publishing date	2020-05-14
Publishing country	United States
Document type	Letter
ZDB-ID	304227-3
ISSN	1497-0015 ; 0008-4824 ; 0706-7437
ISSN (online)	1497-0015
ISSN	0008-4824 ; 0706-7437
DOI	10.1177/0706743720926798
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 110: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito